enGene Therapeutics Inc. Cash and Restricted Cash
enGene Therapeutics Inc. (ENGN) had Cash and Restricted Cash of $81.52 million as of 2023-10-31, per its 10-K filed 2024-01-29.
Discontinued › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2024-01-29
- 2023-10-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $81.52M.
- 2022-10-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $20.43M.
- 2021-10-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $11.02M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2023-10-31 | $81.52M 10-K · filed 2024-01-29 |
| 2022-10-31 | $20.43M 10-K · filed 2024-01-29 |
| 2021-10-31 | $11.02M 10-K · filed 2024-01-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |